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Background: One in eight women will be affected by breast cancer in her lifetime. Approximately 75% of breast
cancers express estrogen receptor alpha (ERα) and/or progesterone receptor and these receptors are markers for
tumor dependence on estrogen. Anti-estrogenic drugs such as tamoxifen are commonly used to block
estrogen-mediated signaling in breast cancer. However, many patients either do not respond to these therapies
(de novo resistance) or develop resistance to them following prolonged treatment (acquired resistance). Therefore,
it is imperative to continue efforts aimed at developing new efficient and safe methods of targeting ER activity in
breast cancer.
Methods: AB215 is a chimeric ligand assembled from sections of Activin A and BMP2. BMP2’s and AB215’s
inhibition of breast cancer cells growth was investigated. In vitro luciferase and MTT proliferation assays together
with western blot, RT_PCR, and mRNA knockdown methods were used to determine the mechanism of inhibition
of estrogen positive breast cancer cells growth by BMP2 and AB215. Additionally in vivo xenograft tumor model
was used to investigate anticancer properties of AB215.
Results: Here we report that AB215, a chimeric ligand assembled from sections of Activin A and BMP2 with
BMP2-like signaling, possesses stronger anti-proliferative effects on ERα positive breast cancer cells than BMP2. We
further show that AB215 inhibits estrogen signaling by inducing expression of inhibitor of DNA binding proteins
(IDs). Specifically, we demonstrate that knockdown of ID proteins attenuates the anti-estrogen effects of AB215.
Remarkably, we find that AB215 is more effective than tamoxifen in suppressing tumor growth in a xenograft model.
Conclusion: This study shows that IDs have profound role to inhibit estrogen signaling in ERα positive breast
cancer cells, and that engineered TGF-beta ligands may have high therapeutic value.
Keywords: Estrogen receptor-positive breast cancer, Transforming growth factor-β, Bone morphogenetic protein,
Tamoxifen alternative, Inhibitor of DNA binding proteins, Bio-better, AB215Background
Breast cancer is one of the leading causes of death for
women worldwide, particularly in developed countries.
During the early stage of breast cancer progression,
estrogen plays a critical role by enhancing the tumor
cell proliferation [1-4]. Estrogen’s pro-oncogenic effect
is mediated via nuclear estrogen receptors (ER), ERα* Correspondence: choe@salk.edu
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unless otherwise stated.and ERβ, by forming steroid/receptor complexes, which
in turn interact with DNA at estrogen response elements
(EREs) in promoter regions of various genes [5,6]. This
binding of steroid/receptor complex at EREs, requires
co-activators including nuclear receptor co-activator 1
(NCOA1), NCOA2, NCOA3 and aryl hydrocarbon recep-
tor nuclear translocator (ARNT), which are all members
of basic Helix-Loop-Helix (bHLH) family. Moreover, it
was reported that over-expression of NCOAs in breast
cancer cells significantly increased their survival [7].
Tamoxifen is an ER antagonist that is currently a
major drug used in treatment of ERα-positive (ERα+)/d. This is an Open Access article distributed under the terms of the Creative
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competitive antagonist that predominantly blocks the
binding of estrogen, 17-β-Estradiol (E2), to ERs. Tamoxi-
fen treatment causes breast cancer cells to remain at the
G0 and G1 phase of the cell cycle. Moreover, the ER/
tamoxifen complex recruits co-repressors (e.g. Nuclear
receptor co-repressor 1 and 2), which in turn stop the
genes from being turned on by E2 [8]. However, after
prolonged tamoxifen usage, as many as ~30% of breast
cancer patients who initially responded to tamoxifen de-
velop resistance to this drug [9,10]. The mechanism of
tamoxifen resistance remains largely unclear and effect-
ive alternatives have yet to be discovered.
In addition to estrogen, growth factors including many
Transforming Growth Factor-beta (TGF-β) superfamily li-
gands are also key regulators of ER+ breast tumor growth.
Bone morphogenetic protein 2 (BMP2) is a TGF-β super-
family member that possesses high affinity for BMP type I
receptors (e.g. Activin receptor like kinase 3 [ALK3])
[11,12] and utilizes the SMAD1/5/8 signaling pathway to
induce osteogenesis [13] and chondrogenesis [14]. BMP2
is also reported to suppress the proliferation of MCF7
breast cancer cells by regulating the retinoblastoma
[15] and the phosphatase and tensin homolog proteins
[16]. However, in contrast to this anti-oncogenic effect,
BMP2 has also been reported as a pro-oncogene in
breast cancer by promoting cancer cell invasion [17],
increasing hormone-independent cancer growth [18],
and angiogenesis in vitro [19]. Interestingly, it has been
reported that E2 treatment mitigated BMP2-induced
gene transcription as well as osteoblast differentiation
in 2T3 and C2C12 cell lines [20]. Moreover, a BMP2-
responsive reporter assay in breast cancer cells dis-
played a 50% decrease in BMP2 signaling when treated
with E2 [21].
Because BMP2 suppresses estrogen-triggered breast
cancer cell proliferation, we tested the anti-estrogenic ef-
fects of AB215, a chimeric ligand composed of approxi-
mately one third Activin A sequence and two thirds
BMP2 sequence that possesses enhanced BMP2-like ac-
tivity. We show that AB215 has stronger anti-estrogenic
and anti-proliferative effects on breast cancer cells than
BMP2. We further demonstrate that AB215 represses
the proliferation of breast cancer cells by inhibiting E2/
ERα-mediated signaling via a novel mechanism involving
induction of ID proteins. Significantly, we demonstrate
that AB215 suppresses ERα+ tumor growth and tumor
cell proliferation more effectively than tamoxifen in a
xenograft model in vivo.
Methods
Protein preparation
AB215 was prepared as previously described [22]. In
brief, Activin A/BMP2 chimeras (AB2 library) have beenengineered as a mix of six sequence segments originat-
ing from two parental molecules, Activin A and BMP2.
AB215 is one such member of AB2 chimera library,
which consists of two sequence segments from Activin
A and four sequence segments from BMP2 in the order
of BABBBA, where A and B denote corresponding seg-
ments of Activin A and BMP2, respectively. AB215 was
expressed in Escherichia coli and chemically refolded
[22]. After the purification steps of heparin affinity and
C4 reverse phase chromatography, the refolded protein
was lyophilized for storage. BMP2 was purchased from
joint Protein Central (http://jointproteincentral.com). Prior
to use, the lyophilized proteins were reconstituted in 1 mM
hydrochloric acid (HCl) in small volume before diluting by
at least a factor of 100 in a relevant final buffer or media
including phosphate buffered saline (PBS).
Cell culture
T47D and MCF7 cell lines were purchased from American
Type Culture Collection (VA, USA) and SK-BR-3 cell
lines from Korean Cell Line Bank (Seoul, Korea). Cells
were grown at 37°C humidified atmosphere of 5% CO2
in RPMI-1640 medium (Invitrogen, NY, USA) supple-
mented with 10% fetal bovine serum (FBS) (Invitrogen).
All assays were performed in RPMI-1640 without phe-
nol red and supplemented with heat-inactivated and
charcoal-stripped FBS (PAA Labs, Pasching, Austria),
unless stated otherwise.
MTT proliferation assay
Cells were plated on a 96-well plate (BD, NJ, USA)
at 4×103 cells/well with 2 ~ 5% heat-inactivated and
charcoal-stripped FBS. After 24 hours, cells were treated
with BMP2, or AB215, with or without 10nM E2 (Sigma)
in ethanol. The final concentration of ethanol in all the
condition was 0.001% (v/v). After desired period of treat-
ment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reagent (5 mg/ml in PBS, Sigma) was
added and incubated at 37°C until purple precipitation
was visible. MTT crystal was dissolved in 4 mM HCl, 0.1%
NP-40 in isopropanol for 15 minutes and absorbance was
measured at 590 nm and baseline corrected at 700 nm.
Luciferase assay
Cells were plated on a 96-well plate (BD) in Opti-MEM
low serum medium (Invitrogen) at 2 × 104 cells/well
and reverse co-transfected with ID1-Del2-Luc and β-
Galactosidase (β-Gal) using FugeneHD (Roche). After
18 hours of transfection, cells were treated with BMP2
or AB215 with or without 10nM E2. After 24 hours of
treatment, cells were lysed using Luciferase lysis buffer
(Promega) and their luminescence was measured with
plate luminometer (Berthhold, Bad Wildbad, Germany).
Transfection variations were normalized by β-gal.
































Human ID2 FWD- 5′-ATGAAAGCCTTCAGTCCCGT
REV- 5′-TTCCATCTTGCTCACCTTCTT
Human ID3 FWD- 5′-TCATCTCCAACGACAAAAGG
REV- 5′-ACCAGGTTTAGTCTCCAGGAA
Human ID4 FWD- 5′-TGAACAAGCAGGGCGACA
REV- 5′-CGTGCAAAGAAAGAATGAAAG
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Cells were plated on a 6 or 12-well plate (BD) at 2 × 105 or
1 × 105 cells/well supplemented with 5% heat-inactivated
and charcoal-stripped FBS. Cells were treated with 10nM
E2, BMP2 or AB215, and exposed for 48 hours. Cells were
lysed with cell lysis buffer (Cell Signaling, MA, USA) con-
taining 1 mM PMSF and phosphatase inhibitor cocktail
(Roche). Cell lysate’s total protein amount was quantified
using Bradford assay. Proteins were separated on SDS-
polyacrylamide gels transferred to nitrocellulose (GE
healthcare, NJ, USA) or PVDF (Biorad, CA, USA) mem-
brane and analyzed according to the manufacturer’s in-
struction. Trefoil factor 1 (TFF1) antibody was purchased
from Santa Cruz Biotechnology (CA, USA), phosphory-
lated Extracellular signal-regulated kinases1/2 (ERK1/2),
ERK1/2 from Cell Signaling Technology (MA, USA)
and β-actin from Sigma.
Real-time PCR
Cells were plated on a 12-well plate (BD) at 1×105 cells/
well supplemented with 5% heat-inactivated and charcoal-
stripped FBS. After 16 ~ 24 hours, cells were treated with
or without 10nM E2 along with BMP2 or AB215. After
2 ~ 48 hours of treatment, RNA was extracted with
TRIsure (Bioline, London, UK) according to the manu-
facturer’s instruction. cDNA Synthesis was performed
using ReverTra Ace qPCR RT Master Mix with gDNA
remover (Toyobo, Japan) according to the manufac-
turer’s instruction. Analysis of mRNA expression was
determined with quantitative real-time polymerase
chain reaction (qRT-PCR) using Thunderbird SYBR
qPCR mix (Toyobo), and 10 pM primers according to
the manufacturer’s instruction. The sequences of
primers are listed in Table 1. Abundance of mRNA in
each sample was determined by the differences between
the cycle threshold (Cτ) values for each genes and β-actin,
ΔCτ. Relative ratios of mRNA expression levels were de-
fined as 2−ΔΔCτ, where ΔΔCτ =ΔCτsample-ΔCτcontrol, which
reflect changes of mRNA expression levels from treated
cells compared to those from untreated cells. All experi-
ments were performed at least 3 times with triplicate
samples.
mRNA knockdown
Genes of interest were knocked down using small inter-
ference RNA (siRNA) transfection. siRNA duplex was
purchased/synthesized from Bioneer Inc (Korea). Cells
were reverse transfected with siRNA duplex complexed
with Lipofectamine RNAiMAX (Invitrogen) reagent in
serum free RPMI1640 media without phenol red (Invitro-
gen) as specified by manufacturer’s instruction. Briefly,
15 pmol siRNA duplex was diluted in 200 ul serum free
RPMI1640 without phenol red and complexed with Lipo-
fectamine for15 ~ 20 minutes. 1×105 cells in RPMI1640supplemented with10% heat-inactivated and charcoal-
stripped FBS were added to the mixture in each well
in a 12 well plate. Cells were treated with ligands after
24 ~ 48 hours of transfection. We tested 1 ~ 3 siRNAs
from Bioneer to select the most efficient construct.
The following sequences of siRNAs for particular gene
knockdowns were used; ID1- FWD-5′-UCGCAUCUUGU
GUCGCUGA, REV-5′-UCAGCGACACAAGAUGCGA;
ID2- FWD-5′-CUUACUUGGACUGUGAUAU, REV-5′-





control was transfected with AccuTarget Negative control
siRNA (Bioneer). Knockdown (KD) efficiency was deter-
mined by qRT-PCR.
In vivo tumor xenograft model
Continuous E2-releasing pellets for 90 days (Innovative
Research of America, FL, USA) were implanted sub-
cutaneously into 4–6 weeks old KSN/Slc athymic mouse
(n = 5) 3 days before xenograft. MCF7 breast cancer cells
(5×106 cells) were subcutaneously xenografted in 50 μl
RPMI1640 with 50 μl Matrigel Matrix (BD) using 21-
gauge needle on the dorsal side. The ligand injection
started when tumor was visible (after 17 days). Two doses
(0.12 (low) or 0.4 (high) mg/kg of mice) of AB215 and
0.6 mg/kg dose of tamoxifen were subcutaneously
injected, three times a week for 10 weeks (10 weeks total -
low group- ~ 90 ug, high group- ~ 300 ug injected). After
70 days from injection started, mice were sacrificed, and
tumor was surgically removed. Mice were also examined
for tumors in other organs and the spleen size was mea-
sured to evaluate inflammation. All the in vivo experi-
ments were done under the guideline of AAALAC
(Association for Assessment and Accreditation of Labora-
tory Animal Care International). All the procedures were
performed at the Lee Gil Ya Cancer and Diabetes Institute
and approved by Institutional Animal Care and Use Com-
mittee (IACUC No. 2011–0103) at Gachon University in
South Korea.
Immunohistochemistry
Tumor tissues were fixed in formaldehyde, embedded in
paraffin, sectioned, deparaffinized/hydrated and processed
for antigen retrieval by microwaving 3 times for 5 minutes
in 10 mM Tris–HCl/pH9.0 and 1 mM EDTA. The sec-
tions were then incubated with Ki67 antibody (Santa
Cruz Biotechnology) at 4°C overnight and analyzed using
ImmPress peroxidase polymer detection kit (Vector Labs,
CA, USA). Harris Hematoxylin (BBC, WA, USA) was
used for counter stain by following standard protocol.
Cell invasion assay
A fluorometric kit for cell invasion assay was pur-
chased from Cell Biolabs (CA, USA). All the procedures
followed the manufacturer’s protocol. Briefly, 2 × 106 cells
were plated on upper chamber of transmembrane-welled
plates in serum-free RPMI 1640 medium with or without
ligands. Lower chamber contained 10% serum or 10nM
E2. After 18 hours, penetrated cells were analyzed
using CyQuant reagent and quantified by a multi-well
fluorometer.Statistical/graphical analysis
All the numerically quantifiable data have been statisti-
cally analyzed and graphically presented using Prism
software (Graphpad, CA, USA). Column analysis was
performed by one-way ANOVA with Dunnett’s post-
hoc test adjustment.
Results
AB215 strongly induces ID proteins
We previously reported that AB215 signals via SMAD1/
5/8 pathway and possesses enhanced signaling relative to
BMP2 in the C2C12 mouse myoblast cell line [22]. Here
we also show that, as predicted, AB215 does not signal
through SMAD2/3 and, therefore, does not signal in an
Activin A-like manner in HEK293T cells (Additional
file 1: Figure S1). We further examined the signaling
properties of AB215 in human MCF7 breast cancer
cells and found that, similar to what was observed in
C2C12 cells, AB215 produces prolonged and enhanced
SMAD1/5/8 phosphorylation when compared to that
induced by BMP2 (Figure 1A). The level of BMP2-
induced SMAD1/5/8 phosphorylation in MCF7 cells
peaks after 60 minutes and then decreases to basal levels
after 3 hours. By contrast, treatment of these cells with
AB215 results in maximal SMAD1/5/8 phosphorylation
30 min following stimulation and sustained after 6 hours
(Figure 1A). We also used a reporter construct consisting
of the phospho-SMAD1/5/8 responsive ID1 promoter
upstream of a luciferase gene to compare the effects of
BMP2 and AB215 treatment on the human breast can-
cer cell lines MCF7, T47D and SK-BR-3 in the absence
(Figure 1B) or presence (Figure 1C) of E2 treatment.
Our results show that AB215 is more potent and has
greater efficacy than BMP2 in these cell lines and that
E2 does not produce statistically significant effect on
ligand-induced ID1 promoter activation of AB215
(Figure 1B and C). In addition, we used qRT-PCR to
demonstrate that AB215 induces expression levels of all
four ID proteins, ID1, ID2, ID3 and ID4, in MCF7 cells
to a greater extent than BMP2 (Figure 1D).
AB215 inhibits estrogen-induced growth of ERα+ cells
We investigated the ability of AB215 to inhibit the growth
of ERα+ MCF7 and T47D as well as ERα-negative (ERα−)
SK-BR-3 human breast cancer cells. Although MCF7 and
T47D cells are both ERα+, the expression level of ERα
is about 4-fold higher in MCF7 cells than in T47D
(Additional file 2: Figure S2a) [23]. We treated cells
with AB215 or BMP2 in the presence or absence of E2
and found that AB215 inhibits E2-induced growth of
MCF7 (Figure 2A and B) and T47D (Figure 2C and D)
cells. MCF7 (ERα+High) cells were more sensitive to in-
hibition than T47D (ERα+Low) cells. BMP2 also inhibits
MCF7 cell proliferation but to a lesser extent than
Figure 1 (See legend on next page.)
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Figure 1 Enhanced signaling capacity of AB215 compared to BMP2 in breast cancer cells. A) Time course western blot analysis of MCF7
cells was performed after exposing BMP2 and AB215 for indicated time. The arrow points to the ligand-induced upper band. B-C) ID1-driven
Luciferase reporter assay of BMP2 and AB215 for MCF7, T47D and SK-BR-3 cells in the B) absence and C) presence of 10nM E2. Cells were reverse
transfected with ID1-Luciferase reporter plasmid in triplicate. Transfected cells were exposed to ligands for 18 hours. Relative luciferase value has
been normalized with β-gal. The data is shown in means ± SD, (n: number of independent experiments = 3). D) mRNA level of IDs in MCF7 cells.
BMP2 and AB215 induced mRNA expression level of ID1/2/3/4 has been measured by qRT-PCR in MCF7 cells. Cells were exposed to 500 ng/ml of
BMP2 and AB215 for 18 hours. Relative mRNA level was calculated in quadruplicate using ΔΔCτ method with the control and β-actin as a
reference. All data are shown in means + SD, n = 3. (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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proliferation of T47D cells. On the other hand, neither
AB215 nor BMP2 affected proliferation of ERα−, SK-
BR-3 (Figure 2E and 2F). It is important to note that
the anti-proliferative effect of AB215 depends on its
concentration in both MCF7 and T47D cells
(Figure 2G).
One of the key mechanisms of estrogen-induced pro-
liferation of breast cancer cells and tumor progression is
the activation of mitogen activated protein kinase, by
promoting phosphorylation of ERK1/2 [24]. Consistent
with its ability to block estrogen-induced proliferation,
AB215 inhibits estrogen-induced phosphorylation of
ERK1/2 in MCF7 cells and does so more strongly than
BMP2 (Figure 2H).
AB215 blocks estrogen-induced ERK signaling by inducing
ID proteins
Since AB215 inhibits E2-induced growth of ERα+ breast
cancer cells and ERK1/2 signaling, we hypothesized that
AB215 induction of ID proteins plays a role in this in-
hibition. ID proteins belong to bHLH family of tran-
scription factors. They possess a HLH domain that
allows them to heterodimerize with other bHLH tran-
scription factors, but they lack a DNA binding domain
and therefore act as inhibitors of other transcription
factors. Hence, we hypothesized ID proteins may in-
activate HLH co-activators of E2/ER assembly such as
NCOAs and ARNT by forming nonproductive com-
plexes with them and thereby preventing the assembly
competent DNA-binding complexes. To test this hy-
pothesis, we transiently knocked down each of the ID
mRNAs using siRNA in ERαhigh MCF7 cells and inves-
tigated the resulting effect of AB215 treatment on E2-
induced ERK1/2 phosphorylation in these cells. The
efficiency of ID-KD was confirmed by comparing
the ability of control or ID-specific siRNAs to block
AB215-induced ID expression (Figure 3A). Our knock-
down studies revealed that all four ID proteins, but es-
pecially ID2, ID3 and ID4, play key roles in mediating
AB215 inhibition of E2-induced ERK1/2 phosphoryl-
ation (Figure 3B). Furthermore, our results suggest that
these ID proteins are not redundant, but rather that
there is a cooperativity between them in mediating thisinhibition process since the inhibitory effect of AB215 is
severely diminished by knocking down ID2, ID3 or ID4
separately (Figure 3B).AB215 inhibits expression of E2-induced genes
TFF1 is a peptide that is expressed at low levels in nor-
mal breast tissue, [25-27] but at high levels in ERα+
breast carcinomas [28] in response to E2 [29]. Since
TFF1 is strictly controlled by the E2/ERα complex, it
provides a good measure of estrogen signaling in breast
cancer cells and a preliminary clinical study reported a
parallel relationship between the TFF1 high expression
levels and the proliferation of breast cancer cells [30].
Oncogenes Bcl2 [31], c-myc [8,32] and Vascular Endo-
thelial Growth Factor (VEGF) [33] are also reported to
be a breast cancer-specific estrogen-responsive genes.
We investigated the effects of AB215 treatment on the
expression of these genes in the absence or presence
of estrogen treatment in ERαhigh MCF7 cells. RT-PCR
and western blot analysis shows that E2-induced TFF1,
c-myc, Bcl2, and VEGF mRNA (Figure 4A) and TFF1,
c-myc, Bcl2 protein (Figure 4B) levels are increased by
estrogen treatment and this effect is significantly suppressed
by co-administration with AB215.AB215 reduces in vivo growth of breast cancer cells
The anti-proliferative activity of AB215 in vitro prompted
us to investigate its potential anti-tumor effects in vivo.
We compared the effects of AB215 with those of tam-
oxifen, an anti-estrogenic drug widely used to treat ER+
breast cancer patients. AB215 and tamoxifen both ap-
peared to reduce the size of tumor xenografts following
3 months of treatment in the presence of an E2 release
pellet (Figure 5A).
To further compare the effects of AB215 and tamoxi-
fen on tumor progression, we measured the expression
patterns and levels of the nuclear proliferation marker
Ki67. As shown in Figure 5B, both AB215 and tamoxifen
treatments were effective in reducing cancer cell prolif-
eration. However, both the high and low dose AB215
treatments resulted in noticeably lower cancer cell dens-
ity than the untreated and the tamoxifen-treated tumors
(Figure 5C).
Figure 2 (See legend on next page.)
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Figure 2 Anti-proliferative property of AB215 on ERα+ breast cancer cells. A, B) ERα+: MCF7, C, D) T47D and E, F) ERα−: SK-BR-3, cells were
grown in phenol red free RPMI1640 supplemented with 2% heat inactivated charcoal-stripped FBS treated with or without 10nM E2 along with
500 ng/ml BMP2 or AB215 in quintuplicate. Cell proliferation was analyzed by MTT assay (Abs590-700 nm) on 0, 1, 3 and 5 days after the
treatment (n = 3). E2 and AB215 did not affect the proliferation of ERα− cells significantly. The results are presented as means ± SD and their
significance has been analyzed by one-way ANOVA. G) MTT assay of MCF7 and T47D cells at increasing concentration of AB215 in the presence
of 10nM E2. Cells were plated and treated as explained in Figure 2a-f. Cells were analyzed 4 days after the treatment. Data are shown in means +
SD. H) Western blot analysis of E2 induced phosphorylation of ERK1/2. Cells were plated in phenol red free RPMI1640 supplemented with 5% heat
inactivated charcoal-stripped FBS treated with or without 10nM E2 along with 500 ng/ml BMP2 or AB215. Cells were harvested and lysed after
48 hours of exposure for western blot analysis. (* = P≤ 0.05, ** = P≤ 0.01, *** = P ≤ 0.001).
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We constructed the AB2 library of segmental chimeras
between Activin A and BMP2 [22] in order to create
novel ligands with unique structural and functional
properties and the potential to fulfill medical needs. The
present study provides evidence that one of these,
AB215 (BABBBA), can inhibit estrogen signaling and the
growth of estrogen-fueled ER+ breast tumors. From the
three-dimensional structure of the ternary complex of
BMP2, Activin receptor Type II (ActRII)-Extracellular
domain (ECD), and ALK3-ECD [34] it can be inferred
that most of the type II receptor binding site of AB215
consists of Activin A sequence while almost all of its
type I receptor binding site is derived from BMP2. Since
both BMP2 and Activin A utilize the type II receptors
ActRII and ActRIIb, we hypothesized that a chimericFigure 3 AB215 induced IDs cooperatively inhibit E2 activating P-ERK
phenol red free RPMI1640 and plated in phenol red free RPMI1640 supplem
transfected with non-sense siRNA. After 24 hours of transfection, cells were
AB215. After 48 hours of exposure, RNA was extracted for qRT-PCR analysis
using siRNA. mRNA level of each IDs were measured using qRT-PCR to con
means + SD in quadruplicates, n = 3. B) KD samples are analyzed for weste
in two separate blots (Control, ID1, ID2-KDs in one blot and ID3, ID4-KDs inligand that possesses the type I receptor specificity of
BMP2 together with the high affinity type II receptor
binding properties of Activin A may have enhanced
BMP2-like properties. Indeed, AB215 signals via the
SMAD1/5/8 pathway but not the SMAD2/3 pathway
and has increased potency relative to BMP2.
BMP2 can inhibit the progression of many different
types of cancers but its role is also bi-directional since it
is also implicated in tumor progression and angiogenesis
in some cancers. Since BMP2 inhibits proliferation
of ERα+ breast cancer cells, we hypothesized that the
increased BMP2-like signaling activity of AB215 may
augment AB215’s potency in anti-proliferation of ERα+
breast cancer cells. In the present study, we established
that AB215 indeed inhibits E2-induced proliferation of
ERα+ breast cancer cells to a greater extent than BMP2.1/2. MCF7 cells were reverse transfected with siRNA in serum free/
ented with 10% heat inactivated charcoal-stripped FBS. Control was
treated with or without 10nM E2 along with 500 ng/ml BMP2 or
or harvested for western blot analysis. A) KD efficiency of each IDs
firm the effectiveness of mRNA knocked down. Data are shown as
rn blot to detect phosphorylation of ERK1/2. The figure shown is done
another blot). (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P≤ 0.001).
Figure 4 AB215 inhibits estrogen induced signaling. To investigate the effect of AB215 on Estrogen signaling, A) mRNA levels of TFF1, c-myc,
Bcl2 and VEGF and B) protein levels of TFF1, c-myc, Bcl2 were analyzed in MCF7 cells. Cell were exposed to the treatment (500 ng/ml AB215 and
10nM E2) for 48 hours (TFF1, Bcl2, and VEGF) and 2 hours (c-myc). qRT-PCR and western blot analysis was performed as described in Figure 3 and
experimental conditions are same as in Figure 2i. mRNA levels are presented as means + SD of quadruplicate, n = 3 and their significance has
been analyzed by one-way ANOVA (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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on ERα− cells indicating that both ligands exert their
anti-proliferative effects through effects on E2 signaling.
Results led us to conclude that the anti-proliferative
effects of AB215 are not only dependent on the ERα
status, but also on the level of ERα expression since it
had less of an effect on the proliferation and E2-induced
gene expression in T47D cells which express ERα at
lower levels than in MCF7 cells (Additional file 2:
Figure S2a-e). The fact that T47D cells were less suscep-
tible to AB215’s anti-proliferative effects than MCF7
cells (Figure 2B and 2D) strongly indicates that these ef-
fects are at least partially exerted via E2/ERα signaling.
E2-induced phosphorylation of ERK is thought to play
essential role in mediating increases in cellular prolif-
eration. Although the mechanism of E2-induced ERK
phosphorylation remains unclear, epidermal growth fac-
tor receptor, protein kinase Cδ and HER-2/neu have each
been shown to be involved [24]. Here, we show thatAB215 can inhibit E2-induced ERK phosphorylation and
E2/ERα-induced gene expression. Consistent with our
working hypothesis that AB215 blocks E2 signaling by
inhibiting E2/ERα complex binding to EREs of various
genes, we found that ID proteins are significantly up
regulated downstream of AB215 signaling, and thus play
a critical role in mediating inhibition of E2-induced
ERK phosphorylation. We propose that ID proteins may
interfere with the binding of E2/ERα to EREs by seques-
tering the E2/ER co-activator proteins such as NCOA
and ARNT in nonproductive complexes. Intriguingly,
our results also demonstrate that ID proteins act in a
non-redundant and highly cooperative manner. Future
studies will elucidate the precise mechanism through
which ID proteins block E2-induced gene regulation.
Our in vivo studies demonstrate that the anti-
tumorigenic effects of AB215 are similar to those of
tamoxifen, not only in reducing tumor size, but also in
improving tumor grade according to Ki67 expression
Figure 5 (See legend on next page.)
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Figure 5 In vivo anti-proliferation property of AB215. Athymic nude mice implanted with continuous releasing E2 pellet were xenografted
with MCF7 cells in the dorsal region. Low (0.12 mg/kg · injection) or high (0.4 mg/kg · injection) dose of ligand or 0.6 mg/kg tamoxifen was
injected in q2d × 10 (every 2 days for 10 weeks) schedule. A) Collected tumors were measured for volume according to π/6 × (length) × (width) ×
(height) equation (n = 5). Results are presented in means + SD. B) Collected tumors were analyzed to determine levels of nuclear proliferation
marker Ki67 (final magnification 400×). Each section was counter stained with hematoxylin (blue/purple) to distinguish proliferating and non-
proliferating cells. C) The quantification of the images from two different tumor sections representing the total number of cells and the number
of cells labeled with Ki67.
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of high concentration of AB215 had no apparent toxicity
to mice and none of these mice developed abnormalities
such as weight loss (Additional file 3: Figure S3), inflam-
mation or tumorigenesis. Moreover, in vitro cell invasion
assays of AB215-treated MCF7 cells did not show devel-
opment of characteristic metastatic properties. (Additional
file 4: Figure S4).Conclusions
We show that the Activin A/BMP2 chimera AB215
strongly induces ID proteins and thereby interferes with
the pro-proliferative and gene expression effects of E2/
ERα signaling. Furthermore, our results suggest that
this enhanced BMP2-like molecule is at least as efficient
as tamoxifen in reducing the size of tumors resulting
from breast cancer xenografts highlighting its potential
effectiveness for the treatment of breast tumors, espe-
cially those resistant to tamoxifen. This discovery puts
AB215 in a prime position as a novel endocrine thera-
peutic biologic and opens a new inroad to study the
complex mechanisms regulating estrogen-driven cancer
cell proliferation.Additional files
Additional file 1: Figure S1. Activin A signaling ability of AB215. To
analyze the Activin A signaling (SMAD2/3) capacity of AB215, Activin
responsive element (ARE) driven luciferase assay was performed in
HEK293T cells. Cells were reverse co-transfected with ARE-Luciferase and
β-galactosidase plasmid. Transfected cells were treated with Vehicle,
Activin A (100 ng/ml), BMP2 (500 ng/ml) and AB215 (500 ng/ml) for
24 hours and lysed for Luciferase activity. The experiments were done in
triplicates and transfection differences were normalized using β-gal. The
data are shown as means + SD.
Additional file 2: Figure S2. Basal mRNA expression level of
ERαhighMCF7 and ERαlowT47D. Cells were plated in phenol red free
RPMI1640 supplemented with 10% heat inactivated charcoal-stripped FBS
and harvested after 48 hrs for RNA extraction. cDNA was synthesized and
RT-PCR was performed to determine basal expression level of a) Estrogen
signaling components: ERα, TFF1, Bcl2, c-myc and Cathepsin D, b) AB215/
BMP2 signaling components: SMAD1, SMAD5, SMAD8 and SMAD4, c)
AB215/BMP2 receptors: BMPRIa (ALK3), BMPRIb (ALK6) and BMPRII, and d)
Inhibitor of DNA binding proteins (ID): ID1, ID2, ID3 and ID4.
Additional file 3: Figure S3. Lethality test of AB215 in CD-1/ICR mice.
To verify the lethality and ectopic organ bone formation of the AB215 in
the body, AB215 was injected intraperitoneally injected three times a
week for 98 day at two concentrations (15 ug/kg and 600 ug/kg, n = 5).The body weight was measured three times a week and is shown as
mean + SD.
Additional file 4: Figure S4. AB215 (and BMP2) in vitro basal
membrane invasion test. MCF7 and T47D cells were treated as defined
and analyzed for basement membrane matrix invasion ability as
described in the methods section. As an attractant, 10% FBS (a and b)
and 10nM E2(c and d) were used. Results are presented as means + SD.
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